Peter Flynn, Ph.D.

Cofounder and Strategic Advisor

Peter Flynn, Ph.D., is the Cofounder of Artiva and serves as a Strategic Advisor. He has 22 years of biotech industry experience. Prior to Artiva, Dr. Flynn was EVP of Orexigen Therapeutics, where he led clinical development, medical affairs, regulatory affairs, and safety functions. Prior to Orexigen, Dr. Flynn was SVP, Early Program Development at Fate Therapeutics, where he was responsible for the regenerative medicine programs and development of the iPSC platform. Prior to Fate, he was Vice President of Research at Ren Pharmaceuticals. Dr. Flynn started his industry career as one of the first employees at the antibody therapeutics company KaloBios Pharmaceuticals, where as head of biochemistry he helped build both the platform technology and monoclonal therapeutic pipeline. Dr. Flynn holds a B.Sc. in molecular biology from University College London and a Ph.D. in biochemistry from Imperial Cancer Research Fund and was a postdoctoral fellow at the UCSF Cancer Center.